Bayer Dives into Digital Health and AI with New Partnership

This week’s trend of big pharma crossing the aisle to collaborate with medtech and digital health companies continues. This time its pharmaceutical giant Bayer in a licensing agreement with One Drop, a developer of digital therapeutic solutions for diabetes and other chronic conditions. New York-based One Drop also raised $40 million in a series B round that Bayer led. The commercial licensing partnership will have One Drop's platform used in Bayer's bio-digital efforts in therapeutic areas such as oncology, cardiovascular disease, and women's health. With A.I.-powered behavioral recommendations, dedicated one-on-one coaching recognized by the American Diabetes Association, and thousands of app and device integrations, One Drop provides personalized health programs to drive sustainable behavior change as part of a diabetes management plan.  "As part of our strategy to shape the future of healthcare and build new businesses in digital health, we are investing in integrated digital solutions to improve health outcomes through data-driven solutions", said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals, in a release. "This collaboration allows us to obtain access to a world-leading self-care platform for disease management beyond the boundaries of medicines with strong artificial intelligence-driven capabilities that could lead to better healthcare outcomes for people with chronic conditions...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news

Related Links:

This study aims to explore the role of lncRNAs in the glucometabolic action of metformin on skeletal muscle cells.Main methodsMetformin accumulation was assessed using [14C]-metformin. A lncRNA array was used to investigate metformin-regulated lncRNAs in C2C12 skeletal muscle cells. Knockdown studies were applied to evaluate the function of lncRNA Dreh. A colorimetric assay was used for the measurement of medium glucose concentration; glucose transport was assessed using [3H]-2-deoxyglucose; real-time PCR was used for RNA expression analysis, and western blotting was used to assess protein expression in myotubes. A Dreh ov...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionStudies on arthroplasty survival should systematically mention gender and diabetes status and beware of potential group incomparability.Level of evidenceIII, cohort study.
Source: Orthopaedics and Traumatology: Surgery and Research - Category: Orthopaedics Source Type: research
Potential therapeutic effect of SO₂ on fibrosis. Histol Histopathol. 2019 Oct 11;:18169 Authors: Wang XB, Cui H, Du JB Abstract Fibrosis is a pathological feature of most chronic diseases and leads to the dysfunction of various organs. However, there is currently no effective method for treating fibrosis. In recent years, a small gas, sulfur dioxide (SO₂), which can be generated endogenously in mammals, has been found to have vasorelaxation activity, improve cardiac function and decrease myocardial injury. Endogenous SO₂ also mediates the process of fibrosis. Inhibition of endogenous SO₂ can ag...
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research
Publication date: Available online 11 October 2019Source: Life SciencesAuthor(s): Mohammad Amin Javidi, Ayat Kaeidi, Seyedeh Sahar Mortazavi Farsani, Sadegh Babashah, Majid SadeghizadehAbstractAimsAn important obstacle on the way of cell-based therapy is the risk of tumorigenicity in the patients benefit from these transplanted cells due to undifferentiated cells which participate in transplantation. Curcumin, the main compound of spice turmeric -as one of the natural products-was demonstrated to possess effective anti-cancer properties, with no significant effect on normal cells in dose and/or time-dependent manner. Furth...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionsThe use of CST in the face of contamination is not associated with an increase in wound complications, mesh complications, or recurrence.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
Authors: Sui J, He M, Wang Y, Zhao X, He Y, Shi B Abstract Sphingolipid metabolism is dysregulated in type 2 diabetes mellitus (T2DM); however, the focus of previous studies was mostly limited to ceramide (Cer), and only few studies have investigated other metabolites, including sphingosine-1 phosphate (So1P). The present study aimed to examine the involvement of 8 major sphingolipid metabolites, including Cer, glucosyl ceramide (GluCer), lactosyl ceramide (LacCer), sphingomyelin (SM), sphinganine (Sa), So1P, sphingosine (So) and sphinganine-1-phosphate (Sa1P), during the progression of T2DM, and to evaluate the ab...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Germacrone cooperates with dexmedetomidine to alleviate high-fat diet-induced type 2 diabetes mellitus via upregulating AMPKα1 expression. Exp Ther Med. 2019 Nov;18(5):3514-3524 Authors: Sun Y, Li L, Wu J, Gong B, Liu H Abstract The aim of the present study was to investigate the effects of germacrone (GM) and dexmedetomidine (DEX) in treating type 2 diabetes mellitus (T2DM). A high-fat diet (HFD)-induced T2DM rat model was established. The experimental rats were divided into the control group, HFD group, GM treatment group, DEX treatment group and GM + DEX treatment group. In addition, adenosine...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL Abstract Lipopolysaccharide (LPS), a potent endotoxin present in the outer membrane of Gram-negative bacteria, causes chronic immune responses associated with inflammation. In the present study, the association between LPS and the dysbiosis of Gram-negative bacteria in the gut microbiome was determined in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (T2DM-CKD; stages 4 and 5, not on dialysis) compared with healthy individuals. Microbiome diversity was analyzed in patients with T2DM-CKD and healthy controls by sequenci...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Sphingosine-1-phosphate induces islet β-cell proliferation and decreases cell apoptosis in high-fat diet/streptozotocin diabetic mice. Exp Ther Med. 2019 Nov;18(5):3415-3424 Authors: He Y, Shi B, Zhao X, Sui J Abstract Sphingosine-1-phosphate (S1P) has been reported to enhance the function of islet β-cells, providing a potential therapeutic target for diabetes mellitus. In the present study, the effects of S1P on the proliferation and apoptosis of β-cells in type 2 diabetic mice were investigated. The mice were administered intraperitoneal S1P solution daily at a dose of 20 µg/kg f...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Our weekly DiabetesMine advice column looks into the probability that a tick bite can cause type 1 diabetes.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
More News: Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Insulin | Medical Devices | Nutrition | Partnerships | Pharmaceuticals | Women